Lind Global Fund II LP 13D/13G Filings for Seelos Therapeutics, Inc. (SEEL)

Lind Global Fund II LP 13D and 13G filings for Seelos Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2024-02-06
5:26 pm
Purchase
2024-01-30 13G Seelos Therapeutics, Inc.
SEEL
Lind Global Fund II LP 11,022
9.900%
11,022increase
(New Position)
Filing